Job Advert
Principal Pharmaceutical Analyst (ref: 152099)
Scottish Medicines Consortium
£67,285 to £71,978 (Band 8B - pro rata)
Sessional work for up to three months (flexible hours as and when required)
Glasgow/Edinburgh - Hybrid working will apply for the foreseeable future.
The Scottish Medicines Consortium (SMC, http://www.scottishmedicines.org.uk) is part of the Evidence Directorate within Healthcare Improvement Scotland and provides advice about the clinical and cost-effectiveness of new medicines for use within NHSScotland. SMC also has a horizon scanning function, aimed at improving financial and service planning within NHS Boards through the provision of early intelligence on new medicines in development.
We are seeking experienced pharmacists with the ability to work well in a multidisciplinary environment to provide additional capacity for the SMC team. You should have highly developed critical evaluation and analytical skills and excellent oral and written presentation skills. We need someone who is able to prioritise and work well against a background of change and uncertainty, and who is self-motivated, proactive, and innovative.
A key area of responsibility will be supporting the team in the delivery of SMC core outputs (new medicines assessments and horizon scanning reports) to a high standard and contributing to the continued development of processes in the context of evolving policy. You will provide highly specialised expert advice on pharmaceutical, clinical and non-clinical issues to other NHS and non-NHS groups as required. This may include engaging and collaborating with senior NHS clinicians and managers, patient and public partners, as well as the pharmaceutical industry.
This is a sessional opportunity where work may be offered on an 'as and when required' basis with no guarantee of fixed hours.
For an informal discussion, please contact Pauline McGuire, Principal Pharmacist (pauline.mcguire@nhs.scot)
Closing date: 18 June 2023 at midnight
Interviews are anticipated to be held on 30 June 2023 via MS Teams